Alector (ALEC) Return on Capital Employed (2019 - 2026)
Alector (ALEC) posted quarterly Return on Capital Employed of 60.38% for Q1 2026, down 1595.0% year-over-year from 4.04% in Q1 2025, and up 5.27% quarter-over-quarter from 63.74% in Q4 2025.
Alector (ALEC) Return on Capital Employed (2019 - 2026) Analysis & Trends
Alector (ALEC) has reported Return on Capital Employed for 8 consecutive years, with 60.38% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed fell 1595.0% year-over-year to 60.38%; the TTM figure through Mar 2026 stood at 60.38% (down 1595.0% YoY), while the FY2025 annual figure was 50.12%, down 1560.0% from the prior year.
- Return on Capital Employed climbed to 60.38% in Q1 2026 per ALEC's latest filing, from 63.74% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 4.65% in Q2 2022 and bottomed at 63.74% in Q4 2025.
- Historically, Return on Capital Employed has averaged 33.32% across 5 years, with a median of 32.34% in 2023.
- Annual changes were most pronounced in 2022 — Return on Capital Employed soared 6694 bps — and 2023, when it plunged 3096 bps.
- Alector's Return on Capital Employed stood at 19.18% in 2022, then tumbled by 69 bps to 32.34% in 2023, then declined by 22 bps to 39.5% in 2024, then tumbled by 61 bps to 63.74% in 2025, then increased by 5 bps to 60.38% in 2026.
- Business Quant data shows ALEC's Return on Capital Employed at 60.38% in Q1 2026, 63.74% in Q4 2025, and 46.52% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Alector | 218.85 Mn | 46.05 Mn | - | -67.59% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -67.59% |
| Mar 31, 2026 | -60.38% |
| Dec 31, 2025 | -63.74% |
| Sep 30, 2025 | -46.52% |
| Jun 30, 2025 | -45.14% |
| Mar 31, 2025 | -44.44% |
| Dec 31, 2024 | -39.50% |
| Sep 30, 2024 | -46.20% |
| Jun 30, 2024 | -41.14% |
| Mar 31, 2024 | -31.34% |
| Dec 31, 2023 | -32.34% |
| Sep 30, 2023 | -29.85% |
| Jun 30, 2023 | -26.31% |
| Mar 31, 2023 | -21.51% |
| Dec 31, 2022 | -19.18% |
| Sep 30, 2022 | -19.66% |
| Jun 30, 2022 | 4.65% |
| Mar 31, 2022 | -3.89% |
| Dec 31, 2021 | -5.38% |
| Sep 30, 2021 | -6.98% |